CYT Stock Price, Cyteir Therapeutics, . Quote, Chart

Market Summary

USD3.010.00

Market Closed

0.00%

CYT Alerts

1 major insider buys recently.

CYT Stock Price

View Fullscreen

CYT RSI Chart

CYT Valuation

Market Cap

108.6M

Price/Earnings (Trailing)

-3.27

Price/Free Cashflow

-4.21

CYT Price/Earnings (Trailing)

CYT Profitability

Return on Equity

-26.57%

Return on Assets

-25.35%

Free Cashflow Yield

-23.74%

CYT Fundamentals

CYT Earnings

Earnings (TTM)

-33.2M

Earnings Growth (Yr)

68.02%

Earnings Growth (Qtr)

57.97%

Breaking Down CYT Revenue

Last 90 days

-3.2%

Trailing 12 Months

44.0%

How does CYT drawdown profile look like?

CYT Financial Health

Current Ratio

21.89

CYT Investor Care

Shares Dilution (1Y)

2.14%

Diluted EPS (TTM)

-0.95

Tracking the Latest Insider Buys and Sells of Cyteir Therapeutics, Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Mar 20, 2024	leonard braden michael	bought	503,238	2.95	170,589	-
Mar 18, 2024	leonard braden michael	bought	342,469	3.01	113,777	-
Mar 04, 2024	renschler markus md	acquired	10,653	1.69	6,304	president and ceo
Mar 04, 2024	gaiero david g	acquired	4,010	1.69	2,373	chief financial officer
Feb 29, 2024	renschler markus md	acquired	24,350	1.60791	15,144	president and ceo
Feb 29, 2024	gaiero david g	acquired	13,462	1.68594	7,985	chief financial officer
Feb 14, 2024	george jean	acquired	23,913	1.69	14,150	-
Feb 09, 2024	sands stephen h.	acquired	20,498	1.69	12,129	-
Feb 08, 2024	thero john f	acquired	21,679	1.69	12,828	-
Feb 06, 2024	zakrzewski joseph s	acquired	23,913	1.69	14,150	-

Which funds bought or sold CYT recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 25, 2024	Lindbrook Capital, LLC	unchanged	-	-60.00	6,038	-%
Apr 24, 2024	BML Capital Management, LLC	added	12.43	1,118,680	10,998,700	7.25%
Mar 11, 2024	VANGUARD GROUP INC	added	7.27	269,854	2,089,670	-%
Feb 26, 2024	Virtu Financial LLC	sold off	-100	-228,000	-	-%
Feb 15, 2024	JANE STREET GROUP, LLC	new	-	126,470	126,470	-%
Feb 14, 2024	Royal Bank of Canada	new	-	16,000	16,000	-%
Feb 14, 2024	STATE STREET CORP	unchanged	-	9,230	140,305	-%
Feb 14, 2024	CANTOR FITZGERALD, L. P.	sold off	-100	-376,289	-	-%
Feb 14, 2024	CSS LLC/IL	reduced	-2.97	6,258	168,291	0.01%
Feb 14, 2024	BRIDGEWAY CAPITAL MANAGEMENT, LLC	new	-	99,712	99,712	-%

Are Funds Buying or Selling CYT?

Are funds buying CYT calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own CYT

No. of Funds

CYT Alerts

1 major insider buys recently.

Unveiling Cyteir Therapeutics, Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Mar 19, 2024	bml investment partners, l.p.	9.7%	3,483,464	SC 13G/A
Mar 12, 2024	gamco investors, inc. et al	4.20%	1,511,035	SC 13D/A
Feb 14, 2024	lightstone ventures ii, l.p.	6.4%	2,309,901	SC 13G/A
Feb 14, 2024	newtyn management, llc	8.4%	3,021,500	SC 13G
Feb 14, 2024	baker bros. advisors lp	0.0%	0	SC 13G/A
Feb 13, 2024	avidity partners management lp	0%	0	SC 13G/A
Feb 09, 2024	gamco investors, inc. et al	3.66%	1,317,085	SC 13D/A
Feb 07, 2024	bml investment partners, l.p.	9.0%	3,250,008	SC 13G/A
Jan 19, 2024	hedgehog capital llc	6.5%	2,350,385	SC 13G/A
Nov 03, 2023	hedgehog capital llc	5.8%	2,099,882	SC 13G

Recent SEC filings of Cyteir Therapeutics, Inc.

View All Filings

Date Filed	Form Type	Document
Mar 29, 2024	15-12G	15-12G
Mar 25, 2024	4	Insider Trading
Mar 21, 2024	S-8 POS	Employee Benefits Plan
Mar 21, 2024	S-8 POS	Employee Benefits Plan
Mar 21, 2024	S-8 POS	Employee Benefits Plan
Mar 21, 2024	AW	AW
Mar 21, 2024	AW	AW
Mar 21, 2024	AW	AW
Mar 20, 2024	8-K	Current Report
Mar 19, 2024	3	Insider Trading

Peers (Alternatives to Cyteir Therapeutics, Inc.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	41.2B	6.8B	-2.42%	-17.04%	-8.75	6.02	-64.45%	-156.37%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	18.0B	1.8B	-7.18%	-26.90%	-41	9.87	76.23%	61.08%
BMRN	15.4B	2.5B	-8.70%	-12.49%	74.73	6.21	13.74%	186.89%
INCY	11.6B	3.7B	-9.54%	-29.84%	19.41	3.14	8.87%	75.42%
MID-CAP
APLS	6.0B	396.6M	-14.77%	-39.78%	-11.37	15.16	425.83%	18.94%
BBIO	4.4B	-	-19.35%	75.41%	-6.7	60.35	54.84%	-34.79%
AXSM	3.4B	270.6M	-9.32%	0.89%	-14.22	12.57	440.80%	-27.84%
ACAD	2.8B	726.4M	-8.24%	-18.54%	-44.9	3.79	40.45%	71.62%
ARWR	2.7B	240.7M	-22.93%	-36.73%	-9.23	12.18	-1.03%	-92.09%
SMALL-CAP
CPRX	1.8B	398.2M	-8.48%	-5.52%	24.58	4.41	85.90%	-14.05%
NVAX	569.6M	983.7M	-16.08%	-46.16%	-1.05	0.58	-50.36%	17.16%
CRBP	361.2M	881.7K	-3.23%	346.43%	-8.1	466.16	-77.61%	-5.33%
INO	247.0M	4.9M	-18.88%	12.93%	-1.83	50.76	-54.97%	51.71%
IBIO	6.1M	2.1M	-47.62%	62.96%	-0.22	2.14	-13.45%	66.37%

Cyteir Therapeutics, Inc. News

Latest updates

Cyteir Therapeutics, Inc. Earnings Report: Key Takeaways & Analysis

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet											(In Millions)
Description	(%) Q/Q	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2020Q4
Assets	-2.5%	131	134	139	153	162	174	186	195	206	202	-
Current Assets	-2.4%	131	134	138	149	157	170	181	193	204	200	12.00
Cash Equivalents	-3.3%	129	134	137	147	154	166	177	190	200	199	11.00
Net PPE	-51.2%	0.00	0.00	0.00	2.00	2.00	2.00	2.00	2.00	2.00	1.00	1.00
Liabilities	-9.4%	6.00	7.00	4.00	7.00	8.00	11.00	11.00	8.00	8.00	8.00	4.00
Current Liabilities	-9.3%	6.00	7.00	4.00	5.00	6.00	9.00	9.00	8.00	8.00	7.00	3.00
Shareholder's Equity	-2.2%	125	128	135	146	154	164	175	187	198	194	-
Retained Earnings	-2.2%	-162	-159	-150	-138	-129	-118	-106	-92.05	-80.24	-68.50	-49.93
Additional Paid-In Capital	0.3%	288	287	286	284	283	282	281	279	278	262	2.00
Shares Outstanding	0.3%	36.00	36.00	36.00	36.00	35.00	35.00	35.00	35.00	14.00	2.00	2.00

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)														(In Thousands)
Description	(%) Q/Q	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2
Cashflow From Operations	-9.8%	-4,556	-4,149	-10,167	-6,917	-12,567	-10,880	-12,168	-9,617	-12,930	-7,111	-6,374	-	-	-
Share Based Compensation	-22.8%	599	776	1,042	869	1,193	1,365	1,255	1,133	1,072	772	488	-	135	107
Cashflow From Investing	-100.0%	-	153	150	-	-10.00	-111	-191	-503	-394	-114	-178	-	-	-
Cashflow From Financing	-61.7%	164	428	103	147	71.00	5.00	19.00	21.00	14,509	121,667	79,809	-	-	-

CYT Income Statement

2023-09-30

Condensed Consolidated Statements of Operations (Unaudited) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Operating expenses:
Research and development	$ 2,676	$ 8,272	$ 17,391	$ 27,154
General and administrative	2,495	3,487	10,809	10,963
Total operating expenses	5,171	11,759	28,200	38,117
Loss from operations	(5,171)	(11,759)	(28,200)	(38,117)
Other income (expense):
Interest income	1,639	714	4,385	849
Loss on disposal of property and equipment			(925)
Gain on lease terminations and modification			318
Total other income (expense)	1,639	714	3,778	849
Net loss	$ (3,532)	$ (11,045)	$ (24,422)	$ (37,268)
Net loss per share--basic	$ (0.10)	$ (0.31)	$ (0.68)	$ (1.06)
Net loss per share--diluted	$ (0.10)	$ (0.31)	$ (0.68)	$ (1.06)
Weighted-average common stock outstanding--basic	36,030,474	35,329,137	35,647,202	35,283,454
Weighted-average common stock outstanding--diluted	36,030,474	35,329,137	35,647,202	35,283,454

CYT Balance Sheet

2023-09-30

Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 129,242	$ 147,120
Prepaid expenses and other current assets	1,401	2,089
Total current assets	130,643	149,209
Property and equipment, net	105	1,699
Other assets	261	2,324
Total assets	131,009	153,232
Current liabilities:
Accounts payable	508	1,128
Accrued expenses and other current liabilities	5,461	4,187
Total current liabilities	5,969	5,315
Other long term liabilities	9	1,631
Total liabilities	5,978	6,946
Commitments and Contingencies (Note 10)
Stockholders' equity:
Preferred stock, $0.001 par value: 40,000,000 shares authorized as of September 30, 2023 and December 31, 2022; no shares issued and outstanding as of September 30, 2023 and December 31, 2022
Common stock, $0.001 par value: 280,000,000 shares authorized as of September 30, 2023 and December 31, 2022; 36,091,075 and 35,575,694 shares issued as of September 30, 2023 and December 31, 2022, respectively; 36,083,742 and 35,516,249 shares outstanding as of September 30, 2023 and December 31, 2022, respectively	35	35
Additional paid-in capital	287,532	284,365
Accumulated deficit	(162,536)	(138,114)
Total stockholders' equity	125,031	146,286
Total liabilities and stockholders' equity	$ 131,009	$ 153,232

About Cyteir Therapeutics, Inc.

Cyteir Therapeutics, Inc., a clinical-stage biotechnology company, develops and commercializes the oncology therapeutics. Its lead product CYT-0851, an oral investigational drug that inhibits monocarboxylate transporters that is in Phase I/II clinical trial for monotherapy in solid tumors and hematologic malignancies, as well as for combination therapy in solid tumors and hematologic malignancies. Cyteir Therapeutics, Inc. was incorporated in 2012 and is headquartered in Lexington, Massachusetts.

CEO	Dr. Markus F. Renschler M.D.
WEBSITE	https://cyteir.com
INDUSTRY	Biotechnology
EMPLOYEES	46

Cyteir Therapeutics, Inc. Frequently Asked Questions

What is the ticker symbol for Cyteir Therapeutics, Inc.? What does CYT stand for in stocks?

CYT is the stock ticker symbol of Cyteir Therapeutics, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Cyteir Therapeutics, Inc. (CYT)?

As of Thu Apr 25 2024, market cap of Cyteir Therapeutics, Inc. is 108.61 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of CYT stock?

You can check CYT's fair value in chart for subscribers.

What is the fair value of CYT stock?

You can check CYT's fair value in chart for subscribers. The fair value of Cyteir Therapeutics, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Cyteir Therapeutics, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for CYT so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Cyteir Therapeutics, Inc. a good stock to buy?

The fair value guage provides a quick view whether CYT is over valued or under valued. Whether Cyteir Therapeutics, Inc. is cheap or expensive depends on the assumptions which impact Cyteir Therapeutics, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for CYT.

What is 5 year return on Cyteir Therapeutics, Inc.'s stock?

In the past 10 years, Cyteir Therapeutics, Inc. has provided -0.243 (multiply by 100 for percentage) rate of return.